ORYZON to present data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles
MADRID, SPAIN and CAMBRIDGE MA.
• Safety data from the first 90 patients will be presented
• Parametric evolution of the first (blinded) 33 patients that have been treated for 6 months will also be discussed
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will present data from the ongoing Phase IIa clinical trial with vafidemstat in Alzheimer’s disease (AD) named ETHERAL (Epigenetic THERapy in ALzheimer’s Disease) at the 2019 Alzheimer's Association International Conference (AAIC-2019) to be held in Los Angeles (USA) on July 14-18.